文献速递肾癌与肾肿瘤

局限性肾肿块主动监测的中长期肿瘤学结局:系统综述与定量分析

Intermediate- and long-term oncological outcomes of active surveillance for localized renal masses: a systematic review and quantitative analysis.
PubMed 文献 · BJU Int · 2021-05-31

该系统综述纳入18个队列共2066例接受主动监测(AS)的局限性肾肿块患者,中位随访53个月。汇总转移率2.1%、肾癌特异性死亡率1.0%、全因死亡率22.6%;小肾肿块(≤4 cm)转移率1.8%、肾癌特异性死亡率0.6%。AS对精选患者尤其是小肾肿块是安全的中长期管理选择,非小肾肿块数据有限。

要点

  • AS患者汇总转移率2.1%,肾癌特异性死亡率1.0%,全因死亡率22.6%。
  • 小肾肿块(≤4 cm)转移率1.8%、肾癌特异性死亡率0.6%、全因死亡率28.5%。
  • 非小肾肿块(>4 cm)转移率5.1%、肾癌特异性死亡率2.1%,数据有限需进一步评估。

核心结论

  • 主动监测是精选局限性肾肿块患者安全的中长期管理选择,尤其适用于小肾肿块。
  • 非小肾肿块数据有限,当前证据支持在精选患者中进一步评估该策略。
  • 需更多高质量数据才能得出确定性结论。

研究设计与样本

  • 系统综述与定量分析,按PRISMA声明实施并在PROSPERO注册(CRD42021230416)。
  • 纳入随访至少3年的局限性肾肿块主动监测研究,两位作者独立筛选、提取数据并评估偏倚风险。
  • 共分析18个独立队列、2066例患者,采用随机效应模型汇总估计,并按小肾肿块(≤4 cm)与非小肾肿块(>4 cm)进行亚组分析。

主要发现

  • 汇总初始最大肿瘤直径为2.8 cm(95%CI 2.7-3.0),经皮穿刺活检率为28%。
  • 汇总平均年增长率为2.8 mm(95%CI 2.1-3.4)。
  • 在汇总平均随访53个月内,2.1%(95%CI 1.0-3.6)患者发生转移,1.0%(95%CI 0.3-2.1)死于肾细胞癌,22.6%(95%CI 15.8-30.2)死于任何原因。
  • 小肾肿块亚组(9项研究,n=987)转移率1.8%(95%CI 0.5-3.7),肾癌特异性死亡率0.6%(95%CI 0-2.1),全因死亡率28.5%(95%CI 17.4-41.4)。
  • 非小肾肿块亚组(5项研究,239例)转移率5.1%(95%CI 0-17.3),肾癌特异性死亡率2.1%(95%CI 0-8.9),全因死亡率29.1%(95%CI 13.6-47.3)。

关键数值与推荐

  • 纳入标准为主动监测治疗局限性肾肿块且随访至少3年的研究。
  • 主要结局为转移率、肾细胞癌特异性死亡率和全因死亡率。
  • 亚组分析界值:小肾肿块定义为≤4 cm,非小肾肿块定义为>4 cm。

临床怎么用

  • 对精选的局限性肾肿块患者,尤其是小肾肿块,可将主动监测作为安全的中长期管理选项。
  • 非小肾肿块患者选择主动监测需谨慎,当前证据有限,建议进一步评估并个体化决策。
  • 主动监测期间应规律随访,关注转移及肿瘤生长情况。

局限性

  • 纳入标准、定义和随访未标准化。
  • 数据存在异质性,亚组分析患者数量有限。
  • 缺乏高质量研究,无法得出确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate intermediate- and long-term oncological outcomes of active surveillance (AS) for localized renal masses (LRMs). METHODS: This systematic literature review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and registered on PROSPERO (CRD42021230416). Studies on AS for LRMs with at least 3 years' follow-up were eligible. Two review authors independently screened the literature, extracted data, and assessed risk of bias. The primary outcomes were metastasis rate, renal cell carcinoma (RCC)-specific mortality (RCC-SM) and all-cause mortality (ACM). Pooled estimates were obtained from random-effects models. Subgroup analyses were performed for small renal masses (SRMs; ≤4 cm) and non-SRMs (>4 cm). RESULTS: We analysed 18 unique cohorts comprising 2066 patients. The pooled initial maximum tumour size was 2.8 cm (95% confidence interval [CI] 2.7-3.0) and the percutaneous biopsy rate was 28%. The pooled mean annual growth rate was 2.8 mm (95% CI 2.1-3.4). Within a pooled mean follow-up of 53 months, 2.1% (95% CI 1.0-3.6) of patients developed metastatic disease, 1.0% (95% CI 0.3-2.1) died from RCC and 22.6% (95% CI 15.8-30.2) died from any cause. For patients with SRMs (nine studies, n = 987), the pooled metastasis rate was 1.8% (95% CI 0.5-3.7), RCC-SM was 0.6% (95% CI 0-2.1), and ACM was 28.5% (95% CI 17.4-41.4). Across five studies reporting on outcomes of 239 patients with non-SRMs, the pooled metastasis rate was 5.1% (95% CI 0-17.3), RCC-SM was 2.1% (95% CI 0-8.9) and ACM was 29.1% (95% CI 13.6-47.3). This review is limited by non-standardized inclusion criteria, definitions and follow-up, data heterogeneity, limited patient numbers in sub-analyses and absence of high-quality studies. CONCLUSIONS: Active surveillance is a safe intermediate- and long-term management option for well-selected patients with LRMs, especially those with SRMs. Limited data are available for non-SRMs, but current evidence would support further evaluation of this approach in selected patients. It is not possible to draw definitive conclusions until more high-quality data become available.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Klatte T, Berni A, Serni S, et al. Intermediate- and long-term oncological outcomes of active surveillance for localized renal masses: a systematic review and quantitative analysis. BJU Int. 2021. PMID: 34060192. doi:10.1111/bju.15435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。